{Reference Type}: Journal Article
{Title}: Moderately hypofractionated proton beam therapy for localized prostate cancer: 5-year outcomes of a phase II trial.
{Author}: Murakami M;Ishikawa H;Sekino Y;Nishiyama H;Suzuki H;Sugahara S;Iizumi T;Mizumoto M;Okumura T;Keino N;Iizumi Y;Hashimoto K;Gosho M;Sakurai H;
{Journal}: J Radiat Res
{Volume}: 65
{Issue}: 3
{Year}: 2024 May 23
{Factor}: 2.438
{DOI}: 10.1093/jrr/rrae026
{Abstract}: The usefulness of moderately hypofractionated radiotherapy for localized prostate cancer has been extensively reported, but there are limited studies on proton beam therapy (PBT) using similar hypofractionation schedules. The aim of this prospective phase II study is to confirm the safety of a shortened PBT course using 70 Gy relative biological effectiveness (RBE) in 28 fractions. From May 2013 to June 2015, 102 men with localized prostate cancer were enrolled. Androgen deprivation therapy was administered according to risk classification. Toxicity was assessed using Common Terminology Criteria for Adverse Events version 4.0. Of the 100 patients ultimately evaluated, 15 were classified as low risk, 43 as intermediate risk, and 42 as high risk. The median follow-up time of the surviving patients was 96 months (range: 60-119 months). The 5-year cumulative incidences of grade 2 gastrointestinal/genitourinary adverse events were 1% (95% CI: 0.1-6.9) and 4% (95% CI: 1.5-10.3), respectively; no grade ≥ 3 gastrointestinal/genitourinary adverse events were observed. The current study revealed a low incidence of late adverse events in prostate cancer patients treated with moderately hypofractionated PBT of 70 Gy (RBE) in 28 fractions, indicating the safety of this schedule.